Facing death, returning to life
A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness
Bibliographic Data
| ID | 15529210 |
|---|---|
| Authors | William P Barone (0000-0002-5108-0149, corresponding author), William Barone, Michiko Mitsunaga-Whitten (Behavior Therapy Associates), Lia Osunfunláyò Blaustein (John F. Kennedy University), Phillip Perl (0000-0001-5854-1502, Public Service Electric and Gas (United States)), Marisa Swank (University of Essex), Thomas Cody Swift (Johns Hopkins Medicine) |
| Year | 2022 |
| Volume | 13 |
| Pages | 944849-944849 |
| Publication date | 2022-09-27 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2022.944849 |
| PMID | 36238946 |
| OpenAlex | W4297173008 |
| Language | EN |
| Citations received | 4 |
| References cited | 36 |
Anxiety associated with life-threatening illness (LTI) is a pervasive mental health issue with a wide impact. A spectrum of traditional pharmacotherapies and psychotherapies are available, but offer varying success in reducing symptoms and improving quality of life. We explore a novel therapy for this condition by assessing prominent thematic elements from participant narrative accounts of a pilot phase 2 clinical trial of 3,4 Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) for treating anxiety associated with LTI. Semi-structured qualitative interviews were conducted with a subset of adult participants 3 months following completion of this trial. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the clinical trial to further understand the process and outcomes of the treatment. Interviews were coded and analyzed using an Interpretative Phenomenological Analysis (IPA) methodological framework. Participants described in detail their experiences from before, during and after the trial, which were analyzed and categorized into thematic clusters. Specifically, participants explored what they felt were important elements of the therapeutic process including processing trauma and grief, exploring mystical and existential experiences, engaging with the present moment with reduced physiological activation, and facing illness and existential fears. Outcomes of the treatment included increased ability to cope with LTI, reduced psychological symptoms, improved vitality and quality of life, and feeling more resourced. Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse. These findings are compared to similar treatments for the same indication. Limitations and challenges encountered in conducting this study are discussed along with implications for theory and clinical treatment
Anxiety · Feeling · Grief · Interpretative phenomenological analysis · Psychiatry · Psychotherapist · Qualitative research · Quality of life (healthcare · Thematic analysis · Vitality · Cannabis and Cannabinoid Research · Clinical Psychology · Complementary and Alternative Medicine Studies · Medicine · Psychedelics and Drug Studies · Psychology · Social Psychology
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
The Body Keeps the Score
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
MDMA-assisted therapy for severe PTSD
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Family caregiver burden
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Using multiple coders to enhance qualitative analysis
Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner
Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction
Interpretative Phenomenological Analysis (IPA)
MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Patient Experiences of Psilocybin-Assisted Psychotherapy
Cancer at the Dinner Table
Sample Size in Qualitative Interview Studies
| Unique citing works | 4 |
|---|---|
| Citations per year | 1,33 |
| Citation span | 2023 - 2025 (3) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 4 |